DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,337,036 | +5.3% | 5,389 | +1.9% | 0.18% | +1.1% |
| Q2 2023 | $1,269,289 | -3.8% | 5,289 | +0.2% | 0.18% | -13.7% |
| Q1 2023 | $1,319,270 | -12.9% | 5,281 | -7.4% | 0.21% | -28.4% |
| Q4 2022 | $1,513,868 | +6.3% | 5,704 | +3.5% | 0.30% | -1.7% |
| Q3 2022 | $1,424,000 | +1.4% | 5,513 | -0.4% | 0.30% | +1.3% |
| Q2 2022 | $1,404,000 | -10.7% | 5,537 | +4.6% | 0.30% | +3.1% |
| Q1 2022 | $1,573,000 | +3.0% | 5,291 | -1.0% | 0.29% | +16.1% |
| Q4 2021 | $1,527,000 | +7.7% | 5,345 | +7.4% | 0.25% | -2.7% |
| Q3 2021 | $1,418,000 | 0.0% | 4,978 | 0.0% | 0.26% | 0.0% |
| Q2 2021 | $1,418,000 | +19.0% | 4,978 | -6.0% | 0.26% | +8.5% |
| Q1 2021 | $1,192,000 | -3.2% | 5,297 | -4.5% | 0.24% | -7.8% |
| Q4 2020 | $1,232,000 | +5.3% | 5,547 | +2.5% | 0.26% | -21.5% |
| Q3 2020 | $1,170,000 | +33.1% | 5,412 | +8.8% | 0.32% | +7.6% |
| Q2 2020 | $879,000 | -55.1% | 4,972 | -63.0% | 0.30% | +259.5% |
| Q1 2020 | $1,958,000 | +147.5% | 13,423 | +160.5% | 0.08% | +1.2% |
| Q4 2019 | $791,000 | +11.9% | 5,153 | +5.3% | 0.08% | +5.1% |
| Q3 2019 | $707,000 | +4.7% | 4,894 | +3.7% | 0.08% | -73.1% |
| Q2 2019 | $675,000 | +50.0% | 4,721 | +8.2% | 0.29% | +12.2% |
| Q4 2018 | $450,000 | +6.1% | 4,362 | +11.8% | 0.26% | +15.4% |
| Q3 2018 | $424,000 | +10.1% | 3,900 | 0.0% | 0.23% | -1.3% |
| Q2 2018 | $385,000 | -1.0% | 3,900 | -1.9% | 0.23% | -35.4% |
| Q1 2018 | $389,000 | +13.1% | 3,974 | +7.2% | 0.36% | +6.3% |
| Q4 2017 | $344,000 | +6.8% | 3,708 | -1.3% | 0.34% | -0.9% |
| Q3 2017 | $322,000 | +3.5% | 3,755 | +1.8% | 0.34% | -42.1% |
| Q2 2017 | $311,000 | +6.5% | 3,688 | +8.2% | 0.58% | +33.0% |
| Q1 2017 | $292,000 | -99.9% | 3,409 | -56.3% | 0.44% | +18.3% |
| Q4 2016 | $303,719,000 | +80462.1% | 7,796 | +62.0% | 0.37% | -18.5% |
| Q3 2016 | $377,000 | -18.9% | 4,811 | +4.4% | 0.46% | -25.2% |
| Q2 2016 | $465,000 | +6.7% | 4,607 | +0.2% | 0.61% | -4.3% |
| Q1 2016 | $436,000 | +0.9% | 4,600 | -1.1% | 0.64% | +4.4% |
| Q4 2015 | $432,000 | +9.1% | 4,651 | +0.1% | 0.61% | +13.0% |
| Q3 2015 | $396,000 | +38.5% | 4,648 | +39.0% | 0.54% | +36.5% |
| Q2 2015 | $286,000 | +38.2% | 3,343 | +36.8% | 0.39% | +28.3% |
| Q1 2015 | $207,000 | -1.0% | 2,443 | +0.1% | 0.31% | +12.0% |
| Q4 2014 | $209,000 | – | 2,441 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |